title: Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer: A network meta-analysis.
abstract: Ovarian cancer (OC) is the 5th leading cause of cancer-related deaths around the world, and several chemotherapy regimens have been applied in the treatment of OC. We aim to compare toxicities of different chemotherapy regimens in the treatment of advanced ovarian cancer (AOC) using network meta-analysis.
  
  
  
  Literature research in Cochrane Library, PubMed, and EMBASE was performed up to November 2015. Eligible randomized controlled trials (RCTs) of different chemotherapy regimens were included. Network meta-analysis combined direct and indirect evidence to assess pooled odds ratios (ORs) and draw the surface under the cumulative ranking (SUCRA) curves.
  
  
  
  Thirteen eligible RCTs were included in this network meta-analysis, including 8 chemotherapy regimens (paclitaxel + carboplatin [PC], pegylated liposomal doxorubicin [PLD] + carboplatin, carboplatin, gemcitabine + carboplatin, paclitaxel, PC + epirubicin, PC + topotecan, docetaxel + carboplatin). Gemcitabine + carboplatin regimen exerted higher incidence of anemia when compared with carboplatin and paclitaxel regimens. The incidence of febrile neutropenia of gemcitabine + carboplatin regimen was higher than that of PC, PLD + carboplatin, carboplatin, and PC + topotecan regimens. Topotecan PC + epirubicin regimen had a higher toxicity, comparing with PC, PLD + carboplatin, and PC + topotecan regimens. As for thrombocytopenia, gemcitabine + carboplatin chemotherapy regimen produced an obviously higher toxicity than PC and carboplatin. As for nausea, PLD + carboplatin chemotherapy regimen had a significantly higher toxicity than that of carboplatin chemotherapy regimen. Moreover, when compared with PC and carboplatin chemotherapy regimens, the toxicity of PC + epirubicin was greatly higher to patients with AOC.
  
  
  
  The nonhematologic toxicity of PLD + carboplatin regimen was higher than other regimens, which was clinically significant for the treatment of AOC.
authors.affiliation: Department of Gynecology & Obstetrics, Huaihe Hospital of Henan University, Kaifeng
authors.forename: Chang-Ping
authors.initials: CP
authors.lastname: Qu
authors.affiliation: Department of Gynecology & Obstetrics, Huaihe Hospital of Henan University, Kaifeng
authors.forename: Gui-Xia
authors.initials: GX
authors.lastname: Sun
authors.affiliation: Department of Gynecology & Obstetrics, Huaihe Hospital of Henan University, Kaifeng
authors.forename: Shao-Qin
authors.initials: SQ
authors.lastname: Yang
authors.affiliation: Department of Gynecology & Obstetrics, Huaihe Hospital of Henan University, Kaifeng
authors.forename: Jun
authors.initials: J
authors.lastname: Tian
authors.affiliation: Department of Gynecology and Obstetrics, Southern Medical University, Guangzhou, P.R. China.
authors.forename: Jin-Ge
authors.initials: JG
authors.lastname: Si
authors.affiliation: Department of Gynecology and Obstetrics, Southern Medical University, Guangzhou, P.R. China.
authors.forename: Yi-Feng
authors.initials: YF
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents